The effectiveness and value of novel acute treatments for migraine

• DOI: 10.18553/jmcp.2020.26.11.1456
• Publication Date: 2020-10-29T17:38:57Z
• Authors: Foluso Agboola; Steven J Atlas; Daniel R Touchette; Eric P Borrelli; David M Rind; Steven D Pearson
• Keywords: Triptans; Acute migraine; Rizatriptan; Migraine treatment; Migraine Disorders

DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, Harvard Pilgrim Care, and Kaiser Foundation Plan to the Institute Clinical Economic Review (ICER), an independent organization that evaluates evidence on value of health care interventions. ICER's annual policy summit is supported dues from Aetna, America's Insurance Plans, Anthem, Allergan, Alnylam, AstraZeneca, Biogen, Blue Shield CA, Boehringer-Ingelheim, Cambia Services, CVS, Editas, Express Scripts, Genentech/Roche, GlaxoSmithKline, Pilgrim, Service Corporation, HealthFirst, Partners, Johnson & (Janssen), Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark United Healthcare. Agboola, Borrelli, Rind, Pearson are employed ICER. Touchette, through University Illinois at Chicago, received funding ICER development economic model described in publication. Atlas has nothing disclose.